Table 3.
Stratified meta-analysis and metaregression of the association of DM and the risk of gout.
| Covariates | No. of study | RR (95% CI) | I 2 (%) | Ph∗ | Metaregression | ||
|---|---|---|---|---|---|---|---|
| Tau2 | Adj − R2 (%) | Ph∗∗ | |||||
| Overall | 7 | 0.66 (0.59, 0.73) | 89.2 | <0.000 | |||
| Subgroup analyses | |||||||
| Types of DM | 0 .000 | 99.6 | 0.01 | ||||
| DM | 2 | 0.84 (0.68, 1.05) | 22.4 | 0.256 | |||
| T1DM | 2 | 0.42 (0.28, 0.63) | 81.5 | 0.020 | |||
| T2DM | 3 | 0.72 (0.70, 0.74) | 0.0 | 0.415 | |||
| Study design | 0.01 | 26.2 | 0.149 | ||||
| Cohort study | 3 | 0.77 (0.68, 0.88) | 39.7 | 0.191 | |||
| Case-control study | 4 | 0.58 (0.48, 0.69) | 93.7 | <0.000 | |||
| Geographical location | 0.072 | 16.9 | 0.208 | ||||
| Asia | 2 | 0.84 (0.68, 1.05) | 22.4 | 0.256 | |||
| Europe | 5 | 0.62 (0.55, 0.70) | 92.1 | <0.000 | |||
Abbreviations: RR—relative risk; CI—confidence interval; Ph∗—p value for heterogeneity within each subgroup; Ph∗∗—p value for heterogeneity between subgroups in metaregression analysis.